Harm W.
- Country
- Germany
- Department
- Cardiology
Research Overview
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Efficacy of Cyclosporine A Versus Placebo in Reducing Myocardial Damage in Takotsubo Syndrome: A Phase II Randomized, Double-Blind, Placebo-Controlled Study
- A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
Data & Insights
Has run more than one trial at 481 of 1132 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in managing patients with acute coronary syndrome and focuses on innovative therapeutic approaches for cardiovascular event prevention.
- Post-myocardial infarction care
- Preventive cardiology
- Cardiovascular risk management
Particular attention is given to therapeutic strategies that reduce recurrent cardiac events in post-heart attack patients.
Thrombosis Research
The investigator has developed expertise in antithrombotic therapy and its application in cardiovascular disease management.
- Novel anticoagulation approaches
- Secondary prevention strategies
- Cardiovascular pharmacology
Clinical interests include the evaluation of emerging therapeutic agents for cardiovascular protection.
Clinical Outcomes
The investigator focuses on major adverse cardiovascular events and their prevention in high-risk cardiac patients.
- Cardiovascular mortality reduction
- Stroke prevention
- Standard-of-care optimization
Expertise extends to evaluating therapeutic interventions that enhance cardiovascular outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.